{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116280","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.805095+00:00","generated_at":"2026-06-08T07:31:35.023886+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Barinthus Bio reports Q3 net loss $14.1M; cash $160.3M, runway to Q2 2025","bullets":["Net loss of $14.1M ($0.37 per share) in Q3 2023, compared to $23.8M loss ($0.62 per share) in Q2 2023.","Cash and cash equivalents $160.3M as of Sep 30, 2023; expects runway into Q2 2025.","R&D expenses $15.1M in Q3, up from $13.5M in Q2, driven by VTP-300 HBV and VTP-850 trials.","Upcoming milestones: interim data from two Phase 2 HBV trials at AASLD Nov 2023; Australia submission for VTP-1000 (celiac).","Company changed name from Vaccitech to Barinthus Biotherapeutics in Nov 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116280","json":"https://secwatch.observer/filing/0001104659-23-116280.json","markdown":"https://secwatch.observer/filing/0001104659-23-116280.md","text":"https://secwatch.observer/filing/0001104659-23-116280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923116280/0001104659-23-116280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923116280/tm2330270d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:31:35.023886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7a284d7285e2140251f65950f22fe22cf81c877","claim":"Barinthus Biotherapeutics plc. reported third quarter of 2023 results: net income $14.1 million, EPS $0.37 per share on both basic and fully diluted bases.","evidence_excerpt":"For the third quarter of 2023, the Company generated a net loss attributable to its shareholders of $14.1 million, or $0.37 per share on both basic and fully diluted bases, compared to a net loss attributable to shareholders of $23.8 million, or $0.62 per share on both basic and fully diluted bases in the second quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923116280/0001104659-23-116280-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Net income","value":"$14.1 million"},{"label":"EPS","value":"$0.37 per share on both basic and fully diluted bases"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}